16 Feb 12
Suddenly, perfect storms are developing on the global branding fronts; the top of the agenda is now â€˜namingâ€™ of the brands itself and how will the names survive the rapid changes of massive digitalization of social media where such name identities reside and skate to catch customers via global cyber branding.
15 Feb 12
Ordering, management and workflow efficiency to be optimized using industry-favored software solution
27 Jan 12
The boardroom agendas must raise some of these questions. What are the specific tactical options available for the organization at this stage? What are the hot buttons on name evaluation for national or global cyber name branding? What are the key steps to get current name identity ahead of competitors on fast track basis? What are the new digital platforms for mass-customer-acquisition? What are the methodical steps to market domination via name identity?
20 Jan 12
Recruiters are very busy people, and typically have little time to read and select CVs for any given role. For them itâ€™s a filtering process, often starting with a pile of CVâ€™s and throwing out the bad ones before reading in more detail, the ones that are left. Therefore your task is NOT to get thrown out with the bathwater, and ensure that your CV is one of the ones that makes it past the first cull!
09 Jan 12
As we move into 2012, we are witnessing a fundamental change in healthcare product technology market demands from policymakers and consumers alike and a shift in the regulatory needs of manufacturers in this area.
Shayesteh FÃ¼rst-Ladani, Managing Director
21 Dec 11
The integration of mobile technology, bilingual skills and the use of Recruitment Process Outsourcing for global expansion are amongst the top issues that will dominate Chinaâ€™s recruitment market in 2012, according to recruiting experts Hays.
Kathy Lou Marketing Manager, China HAYS Recruiting expert worldwide
21 Dec 11
Building a team of suitably qualified clinical research professionals within the Asia Pacific region, particularly in China, South Korea, Taiwan and India, has become a critical requirement due to the enormous growth in clinical trial activity in the region.
Paula Mumby, Vice President, Operations, Asia Pacific
09 Dec 11
It is estimated that long term sickness absence costs the UK economy almost Â£9 billion each year due to 140 million days lost as sickness absence. With an already failing economy, it is no wonder then that alongside a number of employment law reforms aimed at tackling the economic crisis, this is another area under scrutiny.
05 Dec 11
Employee Value Propositions (EVP) and attractive incentives are once again in focus as employers consider candidates who have potential rather than solely those who are an exact fit for the role, says recruiting experts Hays.
14 Nov 11
New data on UCBâ€™s anti-TNF biologic certolizumab pegol (Cimzia), disclosed this week in several poster presentations during the annual meeting of the American College of Rheumatology (ACR), show the treatment works well in rheumatoid arthritis (RA) patients irrespective of prior exposure to other biologics, and that results are sustained over 28 weeks.
Olwen Glynn Owen - Pharmiweb Field Reporter
01 Nov 11
Weâ€™re seeing increasing demand for pharma marketing solutions to be based on the iPad, and itâ€™s not hard to see why. The pace at which the industry continues its move away from paper-based detail aids seems to be increasing. But whatâ€™s interesting is that remote â€˜self-serviceâ€™ edetailing does not seem to be growing at the same rate. The predicted disintermediation of the traditional field sales model hasnâ€™t happened.
10 Oct 11
In the aftermath of last yearâ€™s inconclusive General Election â€” and the subsequent emergence of the Coalition Government â€” youâ€™d have been forgiven for thinking that â€˜deficit reductionâ€™ was the only buzzword in town.
06 Oct 11
Merck Serono, a division of Merck KGaA, Darmstadt Germany, in partnership with the European Head and Neck Society (EHNS), will convene an expert panel of physicians, who will issue a call-to-action that will focus on providing tailored information, advice and better support networks to head and neck cancer patients.
03 Oct 11
NICE is a world-renowned, independent organisation responsible for providing national recommendations on the use of new and existing medicines and treatments within the NHS, through the Technology Appraisal Programme. The Scientific Advice Programme provides not-for-profit chargeable consulting services to companies who have products in development that may be referred for future evaluation by NICE.
29 Sep 11
New drug formulations, biological agents, combination therapies and the latest pharmaceutical developments designed to improve outcomes in patients with a wide range of cancers were highlighted at EMCC 2001. Here are just a few of the highlights:
20 Sep 11
Social media has probably become one of the most important forms of communication and interaction to date, and it is here to stay.
31 Aug 11
Esther Dyson the Great Dame of Silicon Valley, at times matriarch to Bill Gates and many other lads on the innovative circuit, wrote a harsh column August 26th on GPS CNN on ICANN gTLD. I like and respect Esther especially her technical background, we have shared the podium, but as this topic deals with the centrality of global corporate nomenclature it demands an authoritative analysis and I feel itâ€™s my responsibility to clarify and taken the liberty to address her entire piece item by item.
17 Aug 11
For recent graduates from science, medicine, or mathematics programs, applying for work in the ever-expanding pharmaceutical industry can be an intelligent choice for both career and financial stability. Depending on the industry upon which you choose to focus, the rules and expectations during the interview process can vary.
17 Aug 11
Almost irrespective of the country you live in, the increasing costs of healthcare are unavoidable. For governments, the stresses are particularly acute, as both aging populations and the increasing cost of treatments add financial pressures year on year. Yet as a new study by the Institute of Fiscal Studies (IFS) confirms, we should not underestimate the extent to which the shape of the state has already changed.
Max Golby - PharmiWeb Field Reporter
27 Jun 11
At a moment when the national discourse on international aid is grounded in pessimism, David Cameronâ€™s pledge to commit Â£814m to help vaccinate the worldâ€™s poorest children provides an necessary reminder of what international aid really can achieve.
31 May 11
Certolizumab pegol (Cimzia Â®) delivered rapid and consistent improvements in a broad range of rheumatoid arthritis (RA) patients after 12 weeks of treatment regardless of whether or not they had received prior TNF inhibitors or whether or not they were receiving concomitant DMARDs, concluded the latest analysis of the Phase III b REALISTIC trial presented at the European League Against Rheumatism (EULAR) meeting in London, May 25-28 (abstract FRI021).
10 May 11
Both drugs are protease inhibitors (PIs) and are designed to block an enzyme that helps the hepatitis C virus replicate. Hepatitis C is a liver disease caused by infection with the hepatitis C virus, which is transmitted through contaminated blood. The infection can cause liver failure and liver cancer.
Rhonda Siddall-Freelance Medical Journalist and Writer